People who are not up to date with screening are at increased risk of colorectal cancer (CRC)
Did you know?
CRC is highly preventable, yet
75% of people who died
from it were due for screening1
CRC is still the 2nd-leading cause of cancer-related deaths2
Compliance rates remain stagnant and low3
| Current CRC screening methods | Compliance rates |
|---|---|
Stool tests4,5 |
14-67% |
Colonoscopies5,6 |
38-50% |
Due to compliance barriers with these existing modalities, many patients continue to go unscreened6,7
Shield™ is an accurate blood test that can help overcome barriers and increase compliance7,8
Shield™ is a blood test that is easy to complete14-16
High compliance rate in real world clinical settings
90%9,*
High compliance rate in real world clinical settings
90%9,*
ECLIPSE validates Shield as a high-sensitivity blood test for CRC screening that is easy to complete
Specificity8,†
90%
Sensitivity8,†
83%
CRC Overall
Offer your patients Shield—the patient-preferred CRC screening test7,10
2.5x more patients say yes to screening with Shield10
GET STARTED*Compliance rate for the first 8,000 patients that were prescribed Shield and completed it.18
Shield™ is a qualitative laboratory developed test intended to detect colorectal neoplasia by identifying genomic and epigenomic alterations in cell-free DNA in plasma from blood collected in Guardant blood collection tubes.
- The assay is intended to be complementary to and not a replacement for current recommended colorectal cancer screening methods
- Patients with an “abnormal signal detected” Shield result should be referred for colonoscopic evaluation
- A “normal signal detected” Shield result does not preclude the presence of colorectal neoplasia, and patients should continue participating in guideline-recommended screening programs
- Shield was developed, and its performance characteristics determined, by the Guardant Health Clinical Laboratory in Redwood City, CA, USA, which is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high complexity clinical testing. This test has not been cleared or approved by the US FDA
References
1. Doubeni CA, Fedewa SA, Levin TR, et al. Modifiable failures in the colorectal cancer screening process and their association with risk of death. Gastroenterology. 2019;156(1):63-74. doi:10.1053/j.gastro.2018.09.040
2. American Society of Clinical Oncology. Colorectal cancer: statistics. Cancer.net website. Updated January 2021. Accessed May 10, 2021. https://www.cancer.net/cancer-types/colorectal-cancer/statistics
3. American Cancer Society. Colorectal Cancer Facts & Figures 2020-2022. Atlanta: American Cancer Society; 2020.
4. Gellad ZF, Stechuchak KM, Fisher DA, et al. Longitudinal adherence to fecal occult blood testing impacts colorectal cancer screening quality. Am J Gastroenterol. 2011;106(6):1125-1134. doi:10.1038/ajg.2011.11
5. Inadomi JM, Vijan S, Janz NK, et al. Adherence to colorectal cancer screening: a randomized clinical trial of competing strategies. Arch Intern Med. 2012;172(7):575-582. doi:10.1001/archinternmed.2012.332
6. Denberg TD, Melhado TV, Coombes JM, et al. Predictors of nonadherence to screening colonoscopy. J Gen Intern Med. 2005;20(11):989-995. doi:10.1111/j.1525-1497.2005.00164.x
7. Liles EG, Coronado GD, Perrin N, et al. Uptake of a colorectal cancer screening blood test is higher than of a fecal test offered in clinic: a randomized trial. Cancer Treat Res Commun. 2017;10:27-31. doi:10.1016/j.ctarc.2016.12.004
8. Chung DC, Gray DM, Greenson J, et al. Clinical validation of a cell-free DNA blood-based test for colorectal cancer screening in an average risk population. Abstract presented at: Digestive Disease Week 2023; May 6-9, 2023; Chicago, IL. #913e.
9. Guardant Health announces positive results from pivotal ECLIPSE study evaluating a blood test for the detection of colorectal cancer. December 15, 2022. Accessed July 6, 2023. https://investors.guardanthealth.com/press-releases/press-releases/2022/Guardant-Health-announces-positive-results-from-pivotal-ECLIPSE-study-evaluating-a-blood-test-for-the-detection-ofcolorectal-cancer/default.aspx
10. Guardant Health, Data on File.
11. National Library of Medicine, ClinicalTrials.gov. Evaluation of the ctDNA LUNAR test in an Average Patient Screening Episode (ECLIPSE). NCT04136002. Available at https://classic.clinicaltrials.gov/ct2/show/NCT04136002. Accessed November 2, 2023.
